Efficacy of dipeptidyl‐peptidase‐4 inhibitors and impact on β‐cell function in Asian and Caucasian type 2 diabetes mellitus patients: A meta‐analysis在亚洲人和白种人的2型糖尿病患者中DPP‐4抑制剂的疗效及对β细胞功能的影响：一项meta分析

Publisher： John Wiley & Sons Inc

E-ISSN： 1753-0407|7|3|347-359

ISSN： 1753-0393

Source： JOURNAL OF DIABETES, Vol.7, Iss.3, 2015-05, pp. : 347-359

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus

By  

CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (ELECTRONIC), Vol. 42, Iss. 10, 2015-10 ,pp. : 999-1024

John Wiley & Sons Inc

Access to resources Recommend Favorite

Safety of Dipeptidyl Peptidase 4 Inhibitors for Treatment of Type 2 Diabetes

By  

Current Drug Safety, Vol. 6, Iss. 5, 2011-11 ,pp. : 304-309

Bentham Science Publishers

Access to resources Recommend Favorite

Dipeptidyl peptidase‐4 inhibitors and the risk of community‐acquired pneumonia in patients with type 2 diabetes

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 4, 2015-04 ,pp. : 379-385

John Wiley & Sons Inc

Access to resources Recommend Favorite

Dipeptidyl peptidase 4 inhibitors attenuates the decline of skeletal muscle mass in patients with type 2 diabetes

By  

DIABETES/METABOLISM: RESEARCH AND REVIEWS (ELECT), Vol. 34, Iss. 2, 2018-02 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy of glucagon‐like peptide‐1 receptor agonists compared to dipeptidyl peptidase‐4 inhibitors for the management of type 2 diabetes: A meta‐analysis of randomized clinical trials

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 20, Iss. S1, 2018-02 ,pp. : 68-76

John Wiley & Sons Inc

Access to resources Recommend Favorite